Aug 11, 2022 8:00am EDT NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
Jun 29, 2022 8:01am EDT NeuBase Therapeutics Announces Promotion of Dr. William Mann to President and COO
May 17, 2022 7:00am EDT NeuBase Presents New Preclinical Data at ASGCT 2022 for Its DM1 Program Demonstrating Wide Tissue Distribution and Supporting a Differentiated Whole-Body Treatment Solution
May 12, 2022 5:00pm EDT NeuBase Therapeutics Reports Business Update and Financial Results for the Second Quarter of Fiscal Year 2022
May 02, 2022 4:30pm EDT NeuBase Therapeutics Announces Presentations at the American Society of Gene & Cell Therapy (ASGCT) 2022 Annual Meeting
Mar 13, 2022 7:00pm EDT NeuBase Therapeutics Presents New Preclinical Data at MDA 2022 for Its Myotonic Dystrophy Type 1 Program Demonstrating Splice Rescue, Nuclear Aggregate Resolution, and Myotonia Reversal
Feb 28, 2022 8:00am EST NeuBase Therapeutics to Present New Preclinical Data for Myotonic Dystrophy Type 1 Program at the 2022 MDA Clinical & Scientific Conference